Ovid Therapeutics (OVID) Competitors

Ovid Therapeutics (NASDAQ:OVID) and Vaxart (NASDAQ:VXRT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

Does the media refer more to OVID or VXRT?

In the previous week, Vaxart had 6 more articles in the media than Ovid Therapeutics. MarketBeat recorded 9 mentions for Vaxart and 3 mentions for Ovid Therapeutics. Vaxart's average media sentiment score of 0.29 beat Ovid Therapeutics' score of 0.16 indicating that Vaxart is being referred to more favorably in the news media.

Company	Overall Sentiment
Ovid Therapeutics	Neutral
Vaxart	Neutral

Which has more volatility & risk, OVID or VXRT?

Ovid Therapeutics has a beta of 0.29, indicating that its share price is 71% less volatile than the S&P 500. Comparatively, Vaxart has a beta of 1.69, indicating that its share price is 69% more volatile than the S&P 500.

Do analysts rate OVID or VXRT?

Ovid Therapeutics presently has a consensus price target of $3.03, suggesting a potential upside of 604.93%. Vaxart has a consensus price target of $4.00, suggesting a potential upside of 692.55%. Given Vaxart's higher probable upside, analysts plainly believe Vaxart is more favorable than Ovid Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Vaxart	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community prefer OVID or VXRT?

Ovid Therapeutics received 47 more outperform votes than Vaxart when rated by MarketBeat users. Likewise, 70.97% of users gave Ovid Therapeutics an outperform vote while only 65.54% of users gave Vaxart an outperform vote.

Company	Underperform	Outperform
Ovid Therapeutics	Outperform Votes 357 70.97%	Underperform Votes 146 29.03%
Vaxart	Outperform Votes 310 65.54%	Underperform Votes 163 34.46%

Which has preferable earnings and valuation, OVID or VXRT?

Ovid Therapeutics has higher earnings, but lower revenue than Vaxart. Vaxart is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$566K	54.03	-$52.34M	-$0.38	-1.13
Vaxart	$20.14M	5.70	-$82.46M	-$0.41	-1.23

Do insiders & institutionals hold more shares of OVID or VXRT?

72.2% of Ovid Therapeutics shares are held by institutional investors. Comparatively, 18.0% of Vaxart shares are held by institutional investors. 13.3% of Ovid Therapeutics shares are held by company insiders. Comparatively, 2.6% of Vaxart shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Is OVID or VXRT more profitable?

Vaxart has a net margin of -431.61% compared to Ovid Therapeutics' net margin of -5,142.56%. Ovid Therapeutics' return on equity of -39.24% beat Vaxart's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	-5,142.56%	-39.24%	-26.19%
Vaxart	-431.61%	-110.46%	-62.78%

Summary

Ovid Therapeutics beats Vaxart on 12 of the 18 factors compared between the two stocks.